SXR1096
Netherton Syndrome
Phase 1Active
Key Facts
About Sixera Pharma
Sixera Pharma is a private, pre-revenue biotech company developing SXR1096, a potential first-in-class topical treatment for Netherton syndrome. The company leverages foundational research by its founders on kallikrein-related peptidases (KLKs) in skin barrier function. Having initiated its first clinical trial in 2021 and secured FDA Rare Pediatric Disease Designation in 2022, Sixera represents a focused effort to address a high-unmet medical need in a rare disease niche. Its development is supported by a network of academic and industrial collaborations.
View full company profileTherapeutic Areas
Other Netherton Syndrome Drugs
| Drug | Company | Phase |
|---|---|---|
| ATR-12 | Azitra | Phase 1 |
| QRX003 (via Quoin Pharmaceuticals) | Skinvisible Pharmaceuticals | Clinical Trials |
| Pipeline Program | MatriSys Bioscience | Preclinical |
| KB104 | Krystal Biotech | Preclinical |
| BCX17725 | BioCryst Pharmaceuticals | Pre-Clinical/Phase 1 |
| QRX003 | Quoin Pharmaceuticals | Phase 2/3 |